Full history for every metric is available with a Kvantra account

Stock profile
Revvity, Inc. logo

Revvity, Inc. (RVTY)

Country: United States of AmericaSector: HealthcareIndustry: Medical - Diagnostics & ResearchExchange: NYSE
P/E TTM
64.3
History
P/E NTM
24.6
Market cap
16.21B
Currency USD
KvantraRankAbout47
IValue44
IIQuality24
IIIMomentum85
Current price
145.22 USD-4.20%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m3,7833,8283,3122,7512,7552,8562,9422,866
Operating profit$m357372
Net profit$m728943569-118296242253614
EPS reported$2.082.26
Operating cashflow per share$5.145.89
Capex per share$0.650.59
FCF per share$4.495.30
Free cash flow$m508592
Net debt$m2,5962,172
Book value equity$m7,2507,271
Book value per share$64.0465.02
Number of sharesm113.21111.83
DPS (TTM paid)$0.280.28

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx46.5164.26
P/B LTMx1.522.23
P/S LTMx3.855.51
P/FCF LTMx21.6327.40
EV/EBITDA LTMx17.7523.33
EV/Sales LTMx4.766.25
Earnings Yield LTM%2.15%1.56%
FCF Yield%4.62%3.65%
Quality
ROE%3.33%3.50%
ROIC%2.82%3.11%
Operating margin%12.49%12.65%
Gross margin%53.08%53.07%
FCF/Sales%17.80%20.11%
Growth and momentum
EPS Growth YoY%-13.69%+13.57%
Sales Growth YoY%+3.67%+4.56%
Net Income Growth YoY%-18.31%+5.88%
FCF Growth%-6.17%+18.92%
Operating Profit Growth%-13.13%-1.35%
Dividend and capital structure
Dividend Yield%0.30%0.19%
Dividend Growth%0.00%0.00%
Payout Ratio%13.93%12.39%
FCF/Debtx0.140.21
Net Debt/EBITDAx3.392.76
EBIT/Net interestx3.874.04
Net debt/market cap%23.62%13.40%
Net debt/Equityx0.360.30
Gross debt/equityx0.480.38

ETFs that hold Revvity

FundTickerPosition#Weight
Xtrackers S&P 500 Equal Weight Scored & Screened UCITS ETF 1CXZEW.L90.44%
iShares ESG Aware MSCI USA Small-Cap ETFESML70.38%
Fidelity Small-Mid Multifactor ETFFSMD70.36%
iShares Healthcare Innovation UCITS ETFHEAL.L31.72%
Invesco S&P 500 Equal Weight Health Care ETFRSPH41.88%
UBS MSCI World Small Cap Socially Responsible UCITS ETF USD accWSCSRI.SW50.69%
JPMorgan Diversified Return U.S. Mid Cap Equity ETFJPME50.48%

Funds with Revvity among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price145.22 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Revvity, Inc. (RVTY)

RVTY · NYSE · Healthcare
145.22 USD-4.20%
Sign up to track this stock
Benchmarks
KvantraRank47
Market cap16.21B
P/E NTM24.6
P/E TTM64.3
KvantraRank?47 / 100
Value
44
Quality
24
Momentum
85
Financialsin USD
20242025TTM2026E
ETFs that hold Revvity
FundTickerPosition#Weight
Xtrackers S&P 500 Equal Weight Scored & Screened UCITS ETF 1CXZEW.L90.44%
iShares ESG Aware MSCI USA Small-Cap ETFESML70.38%
Fidelity Small-Mid Multifactor ETFFSMD70.36%
iShares Healthcare Innovation UCITS ETFHEAL.L31.72%
Invesco S&P 500 Equal Weight Health Care ETFRSPH41.88%
UBS MSCI World Small Cap Socially Responsible UCITS ETF USD accWSCSRI.SW50.69%
JPMorgan Diversified Return U.S. Mid Cap Equity ETFJPME50.48%

Funds with Revvity among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current145.22 USD
Upside
Price consensus
Last year average price target
Current price145.22 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

IndustryMedical - Diagnostics & Research
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free